Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
Annals of Dermatology
;
: 12-18, 2011.
Article
in English
| WPRIM
| ID: wpr-196216
ABSTRACT
BACKGROUND:
Epidermal growth factor receptor (EGFR) inhibitors are being used to treat malignancies originating from epithelia. Unfortunately, blocking the EGFR pathway leads to various side effects, most frequently acneiform eruptions.OBJECTIVE:
To probe the mechanism underlying this side effect, we investigated the effect of EGFR inhibitors on cultured sebocytes.METHODS:
To examine the effects of an EGFR inhibitor (cetuximab, Erbitux(R) 10 ng/ml) and the effects of EGFR ligands, such as epidermal growth factor (EGF, 10 ng/ml) and transforming growth factor-alpha (TGF-alpha, 5 ng/ml), on the production of inflammatory cytokines in cultured sebocytes, we used reverse transcriptase-polymerase chain reaction, immunocytofluorescence and Western blots. Outcomes included the expression of interleukin (IL)-1, IL-6, tumor necrosis factor-alpha (TNF-alpha), peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and EGFR.RESULTS:
There were no significant differences in the expression of IL-1, IL-6, TNF-alpha, PPAR-gamma and EGFR between (a) groups treated with an EGFR inhibitor or an EGFR ligand and (b) the control group, except for a significant increase in the expression of IL-1 in the EGF-treated group.CONCLUSION:
EGFR inhibitors and EGFR ligands do not provoke the expression of inflammatory biomarkers in cultured sebocytes. The role of the sebaceous glands in EGFR inhibitor-induced acneiform eruption should be investigated more thoroughly.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Sebaceous Glands
/
Biomarkers
/
Up-Regulation
/
Blotting, Western
/
Cytokines
/
Interleukins
/
Interleukin-6
/
Interleukin-1
/
Tumor Necrosis Factor-alpha
/
Acneiform Eruptions
Language:
English
Journal:
Annals of Dermatology
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS